Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03689595 · ClinicalTrials.gov registry record
Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
A clinical trial of Multiple Myeloma, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- 30,000
- Enrollment target
- 1
- Study location
NCT03689595 is a study of Multiple Myeloma that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 30,000 participants, above the 478-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (6176% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03689595, a study of Multiple Myeloma, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- 30,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The PROMISE Study aims to establish a prospective cohort of individuals with precursor conditions to multiple myeloma, such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). We will study these patients as a means to identify risk factors for progression to symptomatic multiple myeloma.
Conditions Studied
Interventions
- OTHER Sample of Blood
Study Locations (1)
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30,000 participants |
| Start Date | 2018-10-31 |
| Est. Completion | 2033-10-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03689595
The ClinicalTrials.gov registry entry for NCT03689595 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 30,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 478-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (6176% higher). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Sample of Blood is the first listed.
NCT03689595 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03689595 about?
NCT03689595 is a clinical study titled "Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)". The PROMISE Study aims to establish a prospective cohort of individuals with precursor conditions to multiple myeloma, such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). We will study these patients as a means to identify risk factors for progres...
What is the current status of trial NCT03689595?
This trial is currently recruiting. The enrollment target is 30,000 participants. The study started on 2018-10-31. Estimated completion is 2033-10-31.
What conditions does trial NCT03689595 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT03689595?
The interventions under investigation include: Sample of Blood (OTHER).
Who is sponsoring clinical trial NCT03689595?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03689595 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
RECRUITING · NA
-
Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
RECRUITING
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.